AMPH
Amphastar Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · NMS
$19.74
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$842M
Total market value of the company
11.51
Reasonably valued
5.83
Based on estimated future earnings — lower means cheaper
Rev Growth
+0.4%
Year-over-year revenue change
Profit Margin
11.0%
How much profit the company keeps from each dollar of revenue
10.4%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$22.50
+14% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 6 analysts covering this stock
About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

https://www.amphastar.com

Country: United States Employees: 1,976 Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

DISTRIBUTION
Smart money appears to be selling into strength — caution
-0.579
Returns do not compensate for the risk — negative edge
-0.0729
No positive edge detected — the data suggests staying out
-0.469
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-32.1%
Historical annualised return based on price data
-68.4%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
13
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.97
Less volatile than the market — more defensive
52W High
$31.26
37% below the year high
52W Low
$16.65
19% above the year low
Avg Volume
617,281
Average daily shares traded — higher means easier to buy and sell
6.3
Days it would take all short sellers to cover — higher means more crowded
Short % Float
17.9%
Elevated short interest — bears are positioned against this
N/A
Annual dividend as a percentage of the share price
$1.66
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

88.75
Heavy leverage — higher financial risk if revenues decline
3.85
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
2.73
Like current ratio but excludes inventory — stricter test
Gross Margin
47.3%
Revenue left after cost of goods — higher means pricing power
Operating Margin
8.0%
Profit from core operations before interest and tax
$103M
Positive — the business generates more cash than it spends
Revenue (TTM)
$721M
Total revenue over the last 12 months
Net Income
$79M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
6
Target High
$30.00
Target Median
$22.50
Target Low
$19.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.